VIDEO: Precision medicine benefits patients with NSCLC
Click Here to Manage Email Alerts
In this video, Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson Cancer Center, highlighted a subgroup analysis from the LIBRETTO-001 trial that included patients with RET-fusion positive non-small cell lung cancer and CNS metastases.
Subbiah also noted the update of data from the ARROW study that evaluated the overall response rate and safety of pralsetinib, “a selective and highly potent RET-inhibitor” for the treatment of advanced RET-fusion positive non-small cell lung cancer.
Also presented at ASCO this year were presentations about MET exon 14 skipping (METex14) mutations. Subbiah detailed some findings from a study assessing the duration of response and safety profile of tepotinib (MSC2156119; Merck / EMD Serono) for the treatment of non-small cell lung cancer among patietns with METex14 mutation.
“We are pleased to see another group of lung cancer patients that may benefit from precision medicine,” Subbiah concluded.
References:
- Gainor JF, et al. Abstract 9008. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
- Paik PK, et al. Abstract 9005. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
- Subbiah V, et al. Abstract 9516. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Collapse
Healio Interview
Click Here to Manage Email Alerts